ACE-536-MF-002 (INDEPENDENCE)
A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm- Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Description: This is a double-blind trial that assesses the effectiveness of Luspatercept v's Placebo in patients with Myeloproliferative Neoplasm- Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Study Phase: Phase 3
Principal Investigator: Dr Eibhlin Conneally
Further information